4.5 Article

Transforming growth factor activating kinase 1 regulates extracellular matrix degrading enzymes and pain-related molecule expression following tumor necrosis factor-α stimulation of synovial cells: an in vitro study

Journal

BMC MUSCULOSKELETAL DISORDERS
Volume 18, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/s12891-017-1648-4

Keywords

Synovium; TGF-beta-activated kinase 1; Tumor necrosis factor-alpha; Matrix metalloproteinase 3; A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif; 4, Cyclooxygenase-2; mPGES-1; Nerve growth factor

Funding

  1. JSPS KAKENHI [15K20016]
  2. Uehara Memorial Foundation
  3. Kitasato University Research Grant for Young Researchers
  4. Parents' Association of Kitasato University School of Medicine
  5. Grants-in-Aid for Scientific Research [15K20016] Funding Source: KAKEN

Ask authors/readers for more resources

Background: Recent studies have suggested that the tumor necrosis factor-alpha (TNF-alpha) pathway is a potential target for the management of osteoarthritis (OA). Transforming growth factor (TGF)-beta-activated kinase 1 (TAK1) is essential in several cytokine-mediated cascades, including the TNF-alpha, interleukin-1 (IL-1), and TGF-beta pathways. The role of TAK1 in synovial tissue in OA is not fully understood. Using synovial cells harvested from OA patients during surgery, we investigated whether TAK1 inhibition suppresses production of TNF-alpha-induced extracellular matrix degrading enzymes and expression of pain-related molecules. Methods: Synovial tissues were harvested from ten subjects with radiographic evidence of osteoarthritis (OA) during total knee arthroplasty. Synovial cells were cultured and stimulated with control (culture media), 10 ng/mL human recombinant TNF-alpha, or 10 ng/mL TNF-alpha and 10 mu M of the TAK1 inhibitor (5Z)-7-oxozeaenol for 24 h. Real-time polymerase chain reaction (PCR) analysis was used to monitor expression of mRNA of the extracellular matrix degrading enzymes matrix metalloproteinase-3 (MMP-3) and a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 4 (ADAMTS-4); and of the pain-related molecules cyclooxygenase-2 (COX-2), microsomal prostaglandin E synthase-1 (mPGES-1), and nerve growth factor (NGF). MMP-3 and NGF protein concentrations in cell supernatant were measured by enzyme-linked immunosorbent assay (ELISA). COX-2, mPGES-1 and ADAMTS-4 protein expression was also evaluated by western blotting. Results: TNF-alpha stimulated increases in ADAMTS-4 and MMP3 mRNA (2.0-fold and 1.6-fold, respectively, p < 0.05) and protein expression (21.5-fold and 2.0-fold, respectively). Treatment with the TAK1 inihibitor (5Z)-7-oxozeaenol reduced ADAMTS-4 and MMP3 mRNA (0.5-fold and 0.6-fold, respectively) and protein expression (1.4-fold and 0.5-fold, respectively) in OA synovial cells. COX-2, mPGES-1 and NGF mRNA (11.2-fold, 3.1-fold and 2.7-fold, respectively) and protein expression (3.0-fold, 2.7-fold and 2.2-fold, respectively) were increased by TNF- a. (5Z)-7-oxozeaenol treatment reduced mPGES1 and NGF mRNA (1.5-fold and 0.8-fold, respectively) and protein (1.5-fold and 0.5-fold, respectively). Conclusion: TAK1 plays an important role in the regulation of TNF-alpha induced extracellular matrix degrading enzymes and pain-related molecule expression. TAK1 may be a potential target for therapeutic strategies aimed at preventing osteoarthritis progression and pain.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available